Emerging therapies for AMD management

Video

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Anat Loewenstein, MD, chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel), provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

See more AMD Awareness content here, here, and here.

Recent Videos
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Wooden blocks which say PHASE and a block at the end with the numbers 1/2. The last block is switching from 1 to 2. This represents a clinical trial moving through phases. Image credit: ©rabbitti – stock.adobe.com

First patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)

Hattie Hayes
March 13th 2025
Article

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A close-up of an eyeball looking at the tip of a syringe needle. There is a droplet of liquid coming from the syringe. Concept image for anti-VEGF and diabetic macular oedema. Image credit: ©kikkerdirk – stock.adobe.com

Renal dysfunction negatively impacts effect of diabetic macular oedema therapy

Lynda Charters
March 11th 2025
Article

Additionally, the prognosis of macular oedema may help clinicians evaluate renal function, investigators reported

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The Heidelberg Congress Center in Heidelberg, Germany. Image courtesy of Heidelberg Engineering.

Heidelberg Engineering announces two-day International SPECTRALIS Symposium

Hattie Hayes
March 7th 2025
Article

The event will include presentations on artificial intelligence, ocular imaging and surgical topics

A phone with the US Food and Drug Administration (FDA) logo on the screen. Image credit: ©gguy – stock.adobe.com

US FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2

Martin David Harp;Hattie Hayes
March 6th 2025
Article

The encapsulated cell therapy from Neurotech Pharmaceuticals is the first FDA-approved treatment for MacTel

© 2025 MJH Life Sciences

All rights reserved.